Efficacy of prolonged-release fampridine vs placebo on walking ability, dynamic and static balance and quality-of-life: an integrated analysis of MOBILE and ENHANCE

Supported by: Biogen (Cambridge, MA, USA). Writing and editorial support for the preparation of this abstract was provided by Excel Scientific Solutions (Southport, CT, USA): funding was provided by Biogen. R. Hupperts has received honoraria and research grants from and advisor boards for Biogen, Merck and Sanofi-Genzyme. J. Hobart has received consulting/advisor fees, honoraria and research support from Acorda, Biogen, Brickell Biotec, Genzyme, Global Blood Therapeutics, LORA group, Merck Serono, Novartis, Oxford Pharmogenesis, Roche, Tigercat and Vanita. C. Gasperini has received consulting fees from Bayer HealthCare and Biogen; speaker fees from Bayer HealthCare, Biogen, Genzyme, Merck Serono, Novartis and Teva. J. Lycke has received consulting/speaker fees from and is on advisory boards for Biogen, Genzyme, Novartis, Merck, Sanofi-Aventis and Teva; serves on the editorial board of the Acta Neurologica Scandinavica; has received unconditional research grants from Biogen, Novartis and Teva. T. Ziemssen has served on advisory boards, trial steering committees and data and safety monitoring committees for and has received speaker fees and project support from Bayer HealthCare, Biogen, Elan, Genzyme, Merck Serono, Novartis, Roche, Sanofi-Aventis, Synthon and Teva. P. Feys has served on advisory boards for Biogen and Novartis; has received speaker fees from Excemed and Teva.